West Pharmaceutical Services, Inc. — Q3 2012 Form 10-Q Summary
Business context and reporting period
West Pharmaceutical Services designs and manufactures pharmaceutical packaging components and drug-delivery systems through two reportable segments: Pharmaceutical Packaging Systems and Pharmaceutical Delivery Systems. This unaudited filing covers the three and nine months ended September 30, 2012, compared with the corresponding 2011 periods.
Key financial metrics
| Metric | Q3 2012 | Q3 2011 | 9M 2012 | 9M 2011 |
|---|---|---|---|---|
| Net sales | $303.8 million | $293.6 million | $944.9 million | $896.9 million |
| Gross profit | $90.4 million | $81.4 million | $290.2 million | $254.0 million |
| Gross margin | 29.8% | 27.7% | 30.7% | 28.3% |
| Operating profit | $26.3 million | $26.1 million | $103.6 million | $82.6 million |
| Net income | $14.8 million | $16.9 million | $59.6 million | $56.7 million |
| Diluted EPS | $0.43 | $0.49 | $1.70 | $1.62 |
Operating margins were approximately 8.7% in Q3 and 11.0% for the first nine months, compared with approximately 8.9% and 9.2%, respectively, in the prior-year periods. SG&A was $53.7 million in Q3 and $159.5 million for nine months, representing 17.7% and 16.9% of sales.
Q3 sales increased 3.5%; excluding a $16.8 million unfavorable foreign-exchange impact, sales increased 9.2%. Nine-month sales increased 5.4%; on a constant-currency basis, the increase was 9.9%. Packaging Systems and Delivery Systems generated Q3 sales of $215.9 million and $88.2 million, respectively.
Operating cash flow was $117.6 million for the first nine months, versus $88.9 million in 2011. Capital expenditures were $98.4 million, versus $62.0 million, primarily for the new corporate office and research building, information technology infrastructure, and a new compression-molding plant in China. Ending cash and cash equivalents were $143.2 million, compared with $91.8 million at December 31, 2011.
At September 30, 2012, total debt was $401.4 million, including $362.1 million of long-term debt, versus $349.4 million at year-end 2011. Working capital was $281.7 million, and net debt-to-total invested capital improved to 26.5% from 28.2%.
Material changes versus the prior comparable period
- Gross profit increased 11.1% in Q3 and 14.3% for nine months, supported by pricing, favorable product mix, modest volume growth, and production efficiencies.
- Packaging Systems Q3 operating profit increased 12.6% to $39.2 million; nine-month operating profit increased 24.8% to $143.4 million.
- Delivery Systems Q3 operating profit increased to $4.7 million from $1.7 million; nine-month operating profit increased to $12.5 million from $5.9 million.
- Net income declined in Q3 despite higher operating profit because the effective tax rate increased to 40.4% from 30.0%, including $1.8 million of discrete tax charges.
- For nine months, the effective tax rate increased to 31.7% from 25.7%. The period also included an $11.6 million pretax loss on extinguishment of convertible debt.
- Corporate operating costs increased substantially, primarily due to higher stock-based compensation, incentive compensation, and, for the nine-month period, U.S. pension expense.
Debt, financing, and liquidity developments
- In June 2012, the company repurchased $158.4 million principal amount, or 98.06%, of its convertible debentures for a total cash payment of $165.6 million.
- In July 2012, the company issued $168.0 million of senior unsecured notes due 2022, 2024, and 2027. The weighted-average coupon was 3.87%; including hedging and transaction costs, the estimated effective rate was 4.16%.
- The company entered into a new $300.0 million revolving credit facility expiring in 2017, with an accordion feature potentially increasing capacity to $350.0 million. Borrowing capacity available at September 30, 2012 was $197.3 million.
- The company was in compliance with all debt covenants and stated that cash, operating cash flow, and available credit should meet foreseeable liquidity needs.
Guidance, outlook, risks, and unusual items
The filing does not provide explicit quantitative full-year revenue or earnings guidance. Management expects approximately $0.2 million of additional charges under the 2010 restructuring plan in the fourth quarter of 2012, after which no further charges are expected under that plan.
Management reported continued demand for higher-value pharmaceutical packaging products, contract manufacturing, proprietary administration systems, and the eris safety syringe. The new China plant was expected to begin validation activities in January 2013 and commercial production toward the end of the first quarter of 2013. Completion and final settlement of the new corporate office and research building were expected by early 2013, with a planned $43.0 million term loan beginning in the first quarter of 2013.
- Unusual items included a $3.4 million impairment charge in Q2 related to a Delivery Systems product line facing delays and lower-than-expected demand, $2.5 million of restructuring and other items for nine months, and $0.9 million of SmartDose contingent-consideration revaluation expense.
- Foreign exchange remains a material headwind, particularly involving the Euro, British Pound, Danish Krone, Singapore Dollar, and Japanese Yen.
- Key risks include customer demand and ordering patterns, competition and pricing pressure, regulatory approval and commercialization of customer products, product mix, raw-material and labor costs, supply-chain interruptions, dependence on third-party suppliers including Daikyo, and the cost and timing of research and development.
- Legal proceedings were described as incidental to normal business activities, with no expected material adverse effect. The filing reported no significant changes to previously disclosed commitments and contingencies and no material off-balance-sheet financing arrangements beyond ordinary-course leases, purchase obligations, and letters of credit.
- Management concluded that disclosure controls and procedures were effective as of September 30, 2012, with no material changes to internal control over financial reporting.
Important facts for investors to verify
- Whether pricing, mix, and production-efficiency gains continue to offset foreign exchange, raw-material, wage, and benefit-cost pressures.
- The timing, cost, validation, and commercial ramp-up of the China compression-molding plant and the new corporate office and research building.
- Future cash requirements for the planned $43.0 million term loan, capital expenditures, pension obligations, dividends, and debt maturities.
- Progress and commercial demand for SmartDose, eris, and other proprietary delivery systems, including potential changes in contingent consideration.
- Whether the higher effective tax rate and discrete tax charges persist and how geographic earnings mix affects future tax expense.
- Compliance with leverage and interest-coverage covenants as debt increases.